Skip to main content

Table 1 Patient, tumor, treatment and body composition characteristics at inclusion

From: No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

  Male n = 38 (50%) Female n = 38 (50%) Total n = 76 P-value
Age (years) 60.7 ± 9.1 60.5 ± 11.0 60.6 ± 10.0 0.971
ECOG-PS 1.000
 0–1 35 (92%) 34 (90%) 69 (91%)  
 2 3 (8%) 4 (10%) 7 (9%)  
Tumor type 1.000
 colon 31 (82%) 31 (82%) 62 (82%)  
 rectum 7 (18%) 7 (18%) 14 (18%)  
Number of metastatic sites 0.479
 1 13 (34%) 16 (42%) 29 (38%)  
 ≥ 2 25 (66%) 22 (58%) 47 (62%)  
Treatment regimen 0.163
 XELIRI 19 (50%) 13 (34%) 32 (42%)  
 FOLFIRI 19 (50%) 25 (66%) 44 (58%)  
Weight (kg) 76.4 ± 12.3 57.7 ± 10.8 67.0 ± 14.8 < 0.001
Weight loss (WL) (%) 6.0 ± 6.0 6.0 ± 7.9 6.0 ± 7.0 0.564
WL category 5% cut-off 0.386
 ≤ 5% 19 (58%) 14 (44%) 33 (51%)  
 > 5% 14 (42%) 18 (56%) 32 (49%)  
 Missing 5 (−) 6 (−) 11 (−)  
WL category 10% cut-off 0.941
 ≤ 10% 25 (76%) 23 (72%) 48 (74%)  
 > 10% 8 (24%) 9 (28%) 17 (26%)  
 Missing 5 (−) 6 (−) 11 (−)  
BMI (kg/m2) 25.6 ± 3.8 22.3 ± 4.1 23.9 ± 4.2 < 0.001
BMI category (kg/m2) 0.001
 < 18.5 0 (0%) 7 (18%) 7 (9%)  
 18.5–24.9 16 (42%) 22 (58%) 38 (50%)  
 25–29.9 15 (40%) 8 (21%) 23 (30%)  
 ≥ 30 7 (18%) 1 (3%) 8 (11%)  
SMM index (cm2/m2) 52.9 ± 9.9 37.9 ± 5.4 45.4 ± 10.9 < 0.001
SMD (HU) 40.4 ± 8.9 40.0 ± 11.2 40.2 ± 10.0 0.881
VAT index (cm2/m2) 46.5 ± 28.0 23.8 ± 20.5 35.1 ± 26.9 < 0.001
SAT index (cm2/m2) 45.6 ± 17.5 54.2 ± 30.5 50.0 ± 25.2 0.285
SMM depletion 12 (32%) 28 (74%) 40 (53%) < 0.001
  1. Continuous variables are summarized with mean ± standard deviation and the difference according to gender is tested using Wilcoxon–Mann–Whitney test. Categorical variables were summarized with the number of patients and the frequency, n (%), and the difference according to gender was tested using a Pearson’s chi-squared test or Fisher exact test when necessary
  2. ECOG PS Eastern Cooperative Oncology Group Performance Status, XELIRI bevacizumab + oral capecitabine + irinotecan, FOLFIRI bevacizumab + 5-fluorouracil/leucovorin (5FU/LV) + irinotecan
  3. Weight loss (WL) = (usual weight-weight at inclusion) / usual weight × 100; usual weight was available for 65 patients. BMI Body Mass Index (weight (kg) / height2 (m2)), SMM skeletal muscle mass, SMD skeletal muscle density, HU Hounsfield Units, VAT visceral adipose tissue, SAT subcutaneous adipose tissue
  4. SMM loss thresholds were those defined by Martin et al. [6]
\